Yesterday KSX announced :" exclusive channel partner for several...

Yesterday KSX announced :" exclusive channel partner for several key global markets. This announcement marks the
start of a new era in KSX?s brief commercial history and provides an important platform from which to launch our products into a market of nearly 500 million people and an estimated 50 million asthmatic patients."

WheezoMeter? priced at A$ 450 each, so we can easily work out $22.5 billion market share based on the estimated 50 million asthmatic patients (10%), plus the clinical WheezoMeter? priced $1500--2500 each, so the total number should be $30 billion.

Of course, $30 billion is target only, but you know 10% of this target is already $3.0 billion which I believe should be achieveable.

Simple reasons:

1) WheezoMeter? is cheap, very affordable. (5 times of blood pressure unit.)

2) "Omron Healthcare has a greater than 70% market share for its respiratory nebulizers in numerous countries around the world, that will allow it substantial access to the respiratory and primary care physicians in these countries."